Payment overview · 2025
General Payments
$252.81
14 reported records · 9 companies
Healthcare provider profile · identity verified
Brigitte Danielle King, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MT STERLING, KY · NPI 1780666305
Verified facts
What the public records show
CMS Open Payments records show Brigitte Danielle King, MD received $252.81 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.22 | 29.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.62 | 16.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.35 | 12.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.78 | 9.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.35 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.60 | 6.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.49 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.38 | 6.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.02 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.81 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.41 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 588 | 139 |
| Gabapentin | Gabapentin | 406 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 84 |
| Omeprazole | Omeprazole | 310 | 82 |
| Losartan Potassium | Losartan Potassium | 279 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 78 |
| Eliquis | Apixaban | 265 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 78 |
| Tramadol Hcl | Tramadol Hcl | 239 | 58 |
| Lisinopril | Lisinopril | 207 | 49 |
| Spironolactone | Spironolactone | 202 | 60 |
| Alprazolam | Alprazolam | 199 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 54 |
| Memantine Hcl | Memantine Hcl | 185 | 35 |
| Carvedilol | Carvedilol | 183 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 48 |
| Simvastatin | Simvastatin | 164 | 44 |
| Lorazepam | Lorazepam | 161 | 38 |
| Potassium Chloride | Potassium Chloride | 159 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 57 |
| Trazodone Hcl | Trazodone Hcl | 155 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 149 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 36 |
| Metformin Hcl | Metformin Hcl | 145 | 45 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 143 | 37 |
| Donepezil Hcl | Donepezil Hcl | 137 | 33 |
| Sertraline Hcl | Sertraline Hcl | 133 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 31 |
| Buspirone Hcl | Buspirone Hcl | 125 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 30 |
| Furosemide | Furosemide | 121 | 44 |
| Prednisone | Prednisone | 115 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 32 |
| Clonazepam | Clonazepam | 103 | 12 |
| Ozempic | Semaglutide | 103 | 23 |
| Mirtazapine | Mirtazapine | 100 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 15 |
| Synthroid | Levothyroxine Sodium | 94 | 28 |
| Lamotrigine | Lamotrigine | 92 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 24 |
| Famotidine | Famotidine | 89 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 19 |
| Montelukast Sodium | Montelukast Sodium | 82 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 33 |
| Jardiance | Empagliflozin | 79 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 12 |
| Celecoxib | Celecoxib | 76 | 28 |
| Pregabalin | Pregabalin | 73 | 13 |
| Alendronate Sodium | Alendronate Sodium | 72 | 21 |
| Meloxicam | Meloxicam | 72 | 23 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Valsartan | Valsartan | 67 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 17 |
| Allopurinol | Allopurinol | 65 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 15 |
| Glimepiride | Glimepiride | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 17 |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 12 |
| Levofloxacin | Levofloxacin | 52 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 36 |
| Nystatin | Nystatin | 51 | 25 |
| Januvia | Sitagliptin Phosphate | 49 | 11 |
| Bumetanide | Bumetanide | 48 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 15 |
| Metformin Hcl Er | Metformin Hcl | 47 | 13 |
| Nifedipine Er | Nifedipine | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 22 |
| Estradiol | Estradiol | 45 | 19 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 29 |
| Ondansetron Odt | Ondansetron | 40 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 11 |
| Topiramate | Topiramate | 39 | 13 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Atenolol | Atenolol | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 11 |
| Risperidone | Risperidone | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Fentanyl | Fentanyl | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 14 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 13 |
| Torsemide | Torsemide | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 11 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.81 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, Ozempic, REXULTI, Rybelsus, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error